Clinical Trials Logo

Cancer of Unknown Primary clinical trials

View clinical trials related to Cancer of Unknown Primary.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05241132 Recruiting - Chemotherapy Effect Clinical Trials

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Start date: November 12, 2021
Phase: Phase 2
Study type: Interventional

Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown primary, and provide a better treatment plan for these patients. 1. Primary outcome: Objective response rate (ORR) 2. Secondary outcomes: disease control rate (DCR), duration of remission (DOR), progression-free disease (PFS), overall survival (OS), median PFS, median OS, stratification based on clinical features and PD-L1 expression, adverse reactions (AEs), and quality of life.

NCT ID: NCT04848597 Recruiting - Clinical trials for Cancer of Unknown Primary

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Start date: May 13, 2021
Phase: Phase 2
Study type: Interventional

This trial is a single-center, prospective, single-arm Phase II clinical study. The purpose is to evaluate the efficacy and safety of recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and bevacizumab in the second-line treatment of patients with unknown primary tumors.